Affiliate disclosure: As an Amazon Associate, AgmatineHub earns from qualifying purchases. This helps support our research and content creation, and it does not affect what we recommend. Full disclosure.
If you are researching non-opioid options for nerve pain, agmatine and palmitoylethanolamide (PEA) both turn up, both are sold as supplements rather than drugs in most markets, and both have mechanistic stories that sound plausible. The trial records behind them are not comparable.
PEA has been through multiple double-blind randomised controlled trials and a meta-analysis of them. Agmatine has not. That gap should shape expectations, and it should also be read carefully, because PEA has one high-quality negative trial that rarely appears in supplement marketing.
Key Takeaways
- A 2023 systematic review and meta-analysis restricted to double-blind randomised controlled trials pooled 11 studies covering 774 patients and found PEA reduced pain scores with a standardised mean difference of 1.68 (95 percent CI 1.05 to 2.31) [1].
- A quadruple-blinded placebo-controlled trial of 600 mg daily PEA for 8 weeks in 70 patients with diabetic peripheral neuropathic pain found significant reductions in pain and pain interference, plus improved sleep and reduced IL-6 and CRP [2].
- The result usually left out: a randomised, double-blind, placebo-controlled multicentre trial of ultramicronised PEA as add-on therapy in 73 people with spinal cord injury neuropathic pain found no difference from placebo (p = 0.46) [3].
- Agmatine has no meta-analysis in neuropathic pain. Its strongest recent evidence is a rodent gene-therapy study where spinal arginine decarboxylase delivery reversed established hypersensitivity 266 days after nerve injury [4].
- That rodent study is genuinely striking, but it used an intrathecal viral vector, not an oral supplement, and the distinction matters enormously for what you can expect from a capsule.
- Neither compound was well tolerated by accident: PEA showed no major side effects across the pooled trials [1], and the null SCI trial also reported no excess adverse effects versus placebo [3].
Different Mechanisms, Same Target Problem
PEA is a naturally occurring fatty acid amide produced by many cell types. It is thought to work partly by potentiating endocannabinoid signalling and by damping mast cell and glial activation, which places it on the inflammatory and neuroimmune side of chronic pain.
Agmatine comes at the same problem from the glutamate side. It antagonises NMDA receptors, with particular relevance to the GluN2B subunit in the central nervous system, and inhibits nitric oxide synthase, both of which are involved in the central sensitisation that maintains chronic pain [4].
Both are plausible. Plausibility is cheap. The question is what happened when each was put in front of patients.
The PEA Record
The meta-analysis
A 2023 systematic review in Nutrients searched MEDLINE and Web of Science for double-blind randomised controlled trials comparing PEA against placebo or active comparators in chronic pain. Eleven articles met the bar, describing a combined sample of 774 patients. Pooled with a random-effects model, PEA reduced pain scores with a standardised mean difference of 1.68 (95 percent CI 1.05 to 2.31, p = 0.00001) [1]. Several trials also reported quality-of-life and functional benefits, and no major side effects were attributed to PEA in any study.
An SMD of 1.68 is a large effect. It should be read alongside the usual caveats about small trials in a supplement literature, but it is a real, pooled, double-blind number, which is more than most compounds in this category can offer.
The diabetic neuropathy trial
A single-centre, quadruple-blinded, placebo-controlled trial randomised 70 participants with type 1 or type 2 diabetes and peripheral neuropathic pain to 600 mg PEA or placebo daily for 8 weeks, with 94 percent completion. The PEA group showed significant reductions in total pain and pain interference and in most neuropathic pain symptom subscores, with the exception of evoked pain (p = 0.09). Sleep problems improved significantly, depression scores fell modestly (p = 0.03) while anxiety and stress did not, and IL-6 and CRP were significantly reduced [2].
The trial that complicates the picture
Here is the one that belongs in any honest comparison. A randomised, double-blind, placebo-controlled, parallel multicentre trial tested ultramicronised PEA as add-on therapy for neuropathic pain after spinal cord injury. Seventy-three people were randomised and 68 entered the primary analysis after 12 weeks of treatment.
There was no difference in mean pain intensity between PEA and placebo (p = 0.46). Mean pain score reductions were 0.4 for PEA versus 0.7 for placebo, a difference of means of 0.3 favouring placebo numerically. There was also no effect on spasticity, insomnia, or psychological functioning [3].
That does not invalidate the positive trials. It suggests, as is usually the case in pain research, that the pain mechanism matters: a compound working through neuroimmune modulation may do well in inflammatory or metabolic neuropathy and nothing at all in pain driven by central cord injury.
The Agmatine Record
Agmatine has no meta-analysis in neuropathic pain and a much smaller human literature. What it has instead is unusually strong preclinical work, including one 2023 study in Molecular Therapy that deserves attention precisely because it is easy to over-read.
Investigators delivered an adeno-associated viral vector carrying the gene for arginine decarboxylase, the enzyme that makes agmatine, directly into the intrathecal space of mice and rats. This prevented the development of chronic neuropathic pain after spared nerve injury and persistently reversed established hypersensitivity 266 days after injury. Spinal long-term potentiation was inhibited by both exogenous agmatine and the vector, and was enhanced when animals were treated with antibodies that neutralised agmatine [4].
That last detail is the strongest single piece of evidence that endogenous agmatine genuinely modulates pain neuroplasticity: block it, and the pain machinery gets worse. But note what the intervention was. A viral vector, injected into the spinal canal, engineering local agmatine production. That is not a capsule, and the pharmacokinetics are not comparable: oral agmatine in rats has 29 to 35 percent bioavailability and an oral plasma half-life of 74 to 117 minutes [5].
How to Read the Comparison
If you are deciding today, PEA has the stronger human evidence for neuropathic pain, with the important caveat that it failed cleanly in spinal cord injury pain. Agmatine has a compelling mechanistic case and a small human literature, and its most impressive result used a delivery route unavailable outside a laboratory.
Neither is a replacement for the drugs with regulatory approval in this indication, and neuropathic pain is a condition where self-directed supplement experiments can delay diagnosis of a treatable underlying cause. Nerve pain with a new or changing pattern is a reason to see a clinician, not a reason to reorder.
A Note on the Evidence
Agmatine sulfate is not FDA-approved to diagnose, treat, cure, or prevent any disease. This article is informational only and does not constitute medical advice.
Frequently Asked Questions
Which has better evidence for nerve pain, agmatine or PEA?
PEA, clearly. It has 11 double-blind randomised controlled trials pooled in a 2023 meta-analysis covering 774 patients, with a large pooled effect size of 1.68. Agmatine has no meta-analysis in neuropathic pain. That said, PEA also has one well-conducted negative trial in spinal cord injury pain that supplement marketing rarely mentions.
Did PEA ever fail a trial?
Yes. A randomised, double-blind, placebo-controlled multicentre trial of ultramicronised PEA as add-on therapy in 73 people with spinal cord injury neuropathic pain found no difference from placebo on pain intensity (p = 0.46), and no effect on spasticity, insomnia or psychological functioning. This most likely reflects that the pain mechanism in cord injury differs from inflammatory or diabetic neuropathy.
What was the 266-day agmatine study?
A 2023 rodent study delivered a viral vector carrying the arginine decarboxylase gene into the intrathecal space, so the spinal cord produced its own agmatine. It prevented chronic neuropathic pain from developing and reversed established hypersensitivity 266 days after nerve injury. It is important evidence that agmatine modulates pain neuroplasticity, but it used gene therapy, not an oral supplement.
Can I take agmatine and PEA together?
No study has tested the combination. They act on different systems, PEA on neuroimmune and endocannabinoid signalling and agmatine on NMDA receptors and nitric oxide synthase, so there is no obvious conflict. But combining two poorly-characterised options for a condition that warrants medical assessment is not a strategy, and neuropathic pain should be evaluated by a clinician.
References
- Lang-Illievich K, et al. Palmitoylethanolamide in the Treatment of Chronic Pain: A Systematic Review and Meta-Analysis of Double-Blind Randomized Controlled Trials. Nutrients (2023). PMID 36986081
- A randomized controlled trial assessing the safety and efficacy of palmitoylethanolamide for treating diabetic-related peripheral neuropathic pain. Inflammopharmacology (2022). PMID 36057884
- Andresen SR, et al. Ultramicronized palmitoylethanolamide in spinal cord injury neuropathic pain: a randomized, double-blind, placebo-controlled trial. Pain (2016). PMID 27227691
- Long-term reversal of chronic pain behavior in rodents through elevation of spinal agmatine. Mol Ther (2023). PMID 36710491
- Clements JD, et al. Biodistribution of Agmatine to Brain and Spinal Cord after Systemic Delivery. J Pharmacol Exp Ther (2023). PMID 37770201
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
